This one. Novocure OPtune Phase III was a 695 patient trial. They stopped collecting any and all data 24 months after last patient was enrolled. The trial was never blinded. You were either wearing it and taking standard of care, or you weren't.
Subgroup Their crowning achievement was supposedly this subgroup (43 of 466) of people that wore the device 22 to 24 hours a day. 24.90 median OS.
They pumped three, four and five year survival, despite only 8, 4 and (likely) 1 (respectively) out of 43 actually having lived that long out of 43, and actually only 13 out of 43 still alive strewn out between 25 and 60 months. Can't tell where they are, because he does not bother to provide censor marks for 14 people and doesn't bother to continue graph to 60 months, even though hyping 60 month survival as supposedly 29.3% in the subgroup.
Market Data 
Markets 
AI
